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lysosome inhibitors they ob-
served an increase in LC3-II af-
ter the administration of oleate
or palmitate, which suggested
a fatty acid-induced increase
in autophagic flux.
These interesting findings
strongly suggest that autoph-
agy does indeed increase in
insulin resistance, thus pro-
tecting the b cells against cell
damage. Whether this also
applies to the insulin-sensitive
peripheral tissues remains to
be seen, but it looks likely.
However, rather than conclud-
ing that autophagy is an adap-
tive response to increased in-
sulin resistance (Ebato et al.,
2008), we should consider the
possibility that insulin resis-
tance itself could be the adap-
tive response that activates
autophagy, which in turn protects against
cell death. If this is correct, it would mean
that, even though both glucose and lipid
metabolism are severely disturbed during
insulin resistance, increasing autophagy
takes priority in order to prevent the worst.
In this context, it is noteworthy that moder-
ately defective insulin signaling can actually
enhance life span (Russell and Kahn, 2007).
It is tempting tospeculate that, analogously
with the increase in life span produced by
calorie restriction (Cuervo et al., 2005),
this could perhaps be due at least in part
to enhanced autophagic removal of dam-
aged intracellular structures.
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Figure 1. Regulation of Autophagy by Insulin and Amino Acids and
the Role of Autophagy in Pancreatic b Cells
Activation of mTOR requires input from both insulin and amino acids. Activa-
tion of mTOR stimulates protein synthesis and simultaneously inhibits autoph-
agy via phosphorylation of the protein kinase Atg1. Basal autophagy is
required to maintain b cell islet architecture and function. Stimulated autoph-
agy occurs in response to insulin resistance in b cells. The mechanism by
which free fatty acids (FFAs) stimulate autophagy remains to be elucidated.
Reactive oxygen species (ROS) may be involved.
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Homeostatic regulation of bile acid metabolism and biliary lipid secretion is critical to prevent enterohepatic
diseases. Kaestner and coworkers (Bochkis et al., 2008) show that loss of forkhead box transcription factor
Foxa2 in the liver leads to hepatic injury due to downregulation in the expression levels of bile acid
transporters and detoxification enzymes.
There are several reasons why bile acids
(BA) are fascinating biological molecules.
Their life is strictly connected to the fate
of cholesterol, since their synthesis repre-
sents one critical way to decrease choles-
terol overload. Their function is historically
centered to efficient handling of ingested
lipids. BA drive biliary lipid secretion and
increase the aqueous solubilization in
the gut of otherwise insoluble substances,
such as cholesterol and liposoluble vita-
mins, thus favoring lipid digestion. Also,
they are crucial metabolic players in
energy expenditure, glucose and fatty
acid metabolism (Thomas et al., 2008).
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counterpoised by the risk of detergency/
toxicity in case of excess BA concentra-
tions, which can lead to hepatobiliary
injury and cholestasis (Hofmann, 1999).
Several complementary mechanisms
serve to prevent BA toxicity in the liver,
including reduced synthesis and uptake,
increased intracellular detoxification
(phases I and II) and active biliary secre-
tion (phase III). Recently, Kaestner and
coworkers (Bochkis et al., 2008) showed
that hepatocyte-specific ablation of the
transcription factor Foxa2 in mice leads
to intracellular BA accumulation and
hepatic injury due to dowregulation of
BA transporters and detoxification
enzymes.
BA are synthesized in the liver, secreted
in bile, stored in the gallbladder during
the interprandial period, then released in
the gut mainly in response to food intake.
Ileal absorption efficiently recovers BA,
limiting fecal disposal to less than 5% of
the total pool. Transports in the portal
vein and hepatic re-uptake conclude the
BA enterohepatic circulation. Bile flow
represents the functional link between
liver and intestine, and it is crucial for the
regulation of BA enterohepatic circula-
tion. Any condition of impaired bile flow
is defined as cholestasis, thus sorting
out the molecules orchestrating BA
homeostasis and bile flow is a continuing
priority task.
The synthesis of BA in the liver is guar-
anteed by several enzymes of which
Cyp7a1 represents the main limiting
step, and it is controlled at transcriptional
level via a feedback cascade that starts
with the activation of nuclear bile acid
receptor FXR (Lu et al., 2000; Goodwin
et al., 2000). Hepatic BA uptake at the
basolateral membrane of hepatocytes is
mediated by the organic anion transport-
ing polypeptides (Oatps) and by the Na+
Figure 1. Bile Acid Metabolism in the Hepatocytes under Normal Condition and in Absence
of Foxa2
(A) The hepatocyte membrane is functionally divided in a basolateral (or sinusoidal) and a canalicular side.
On the basolateral side, there are several transporters that regulate the uptake or the secretion of BA in the
systemic circulation. While Oatps and Ntcp are responsible for BA uptake, Mrp3, Mrp4, and Osta/b directly
regulate BA spill over in the blood, especially during cholestatic conditions. Once in the hepatocytes, BA
undergo several changes such as oxidation (phase I, depicted is Cyp3a11) and conjugation (phase II; de-
picted are Gsta1, Gsta2, Gstm2, Sult2a1, Slc27a5, BBAT, Ugt1b6) in order to decrease their own toxicity.
Several enzymes orchestrate BA synthesis, with Cyp7a1 being the rate-limiting step. Elimination of BA by
the hepatocyte (phase III) is guaranteed by the presence of several transporters on the canalicular mem-
brane that actively secrete BA in bile (Bsep, Mrp2, and partly Mdr1).
(B) When Foxa2 is lost, BA metabolism is impaired, with increased intracellular BA concentrations,
reduced BA conjugation, and increased BA toxicity. The final result is liver injury. At molecular levels,
this scenario is explained by the transcriptional downregulation of basolateral (Oatp2, Mrp3, Mrp4) and
canalicular (Mrp2) transporters, together with the decrease in mRNA levels of Cyp3a11, Slc27a5,
and Gsts.Cell Metabolismtaurocholate cotransport protein (Ntcp).
In the hepatocyte, BA undergo phase I
oxidation reactions, which result in more
polar and hydrophilic products. Members
of the cytochrome P450 superfamily, of
which Cyp3a11 represents one of the
main detoxification enzymes, catalyze
BA oxidation. Phase II enzymes are
responsible for conjugation of phase I
products with endogenous molecules to
further increase their water solubility.
Members of the cytosolic sulfotransferase
(SULT) and UDP-glycosyltransferase
(UGT) superfamilies catalyze these reac-
tions. Solubility is also guaranteed via
conversion of BA in BA-CoA esters
through BA-CoA ligase (Slc27a5) and
BA-CoA amino acid N-acyltransferase
(BAAT) (Figure 1A). After phase I and
phase II metabolism, the resulting conju-
gated BA are secreted into the bile (phase
III) via ATP-binding cassette (ABC) trans-
porters, mainly the bile salt export pump
(Bsep, Abcb11), the multidrug-related
protein 2 (Mrp2, Abcc2), and partly the
multidrug protein 1 (Mdr1, Abcb1). These
ABC transporters are expressed at the
canalicular membrane of the hepatocyte
(Figure 1A). On the contrary, ABC trans-
porters such as the multidrug-related
protein 3 (Mrp3, Abcc3) and multidrug-
related protein 4 (Mrp4, Abcc4) are
expressed at the basolateral membrane,
together with the organic anion trans-
porters a and b (OSTa/b), and represent
an alternative route for the liver to spillover
BA in the systemic circulation.
During cholestasis, several adaptive re-
sponses aim at increasing BA detoxifica-
tion and clearance (Trauner et al., 1998).
In patients with cholestatic liver disease,
phase I and phase II reactions are imme-
diately activated. Simultaneously, Ntcp
and Oatp expression are minimized while
Mrp3, Mrp4, and Osta/b are induced to
activate BA secretion at the basolateral
membrane. In normal condition, Mrp3,
Mrp4, and Osta/b are only weakly ex-
pressed, since the preferential exit from
the hepatocyte is the canalicular mem-
brane through Mrp2 and Bsep. However,
during cholestasis, hepatic BA secretion
goes through the basolateral membrane
into the systemic circulation, and this
accounts for the shift of BA elimination
from feces to urine.
Kaestner and coworkers (Bochkis et al.,
2008) recently add new light in BA metab-
olism, showing that the winged helix8, October 8, 2008 ª2008 Elsevier Inc. 277
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their homeostasis. The involvement of
Foxa2 in lipid metabolism has been previ-
ously shown in a gain of function model
(Wolfrum et al., 2004). Also, Kaestner
and coworkers have recently generated
hepatic selective ablation of Foxa2 in
mice, showing a direct role of Foxa2 in
liver development (Sund et al., 2000) and
in the transcriptional response to fasting
(Zhang et al., 2005). Here, they provide
for the first time evidence that absence
of Foxa2 in mouse liver determines
a deep impairment in BA homeostasis.
Using global location analysis, the authors
demonstrate that hepatic deletion of
Foxa2 results in decreased expression
levels of genes involved in BA synthesis,
conjugation, and sinusoidal and canalicu-
lar transport. Although the expression
levels of the main canalicular BA trans-
porter Bsep are unmodified, an increase
in the alternative canalicular BA trans-
porter Mdr1 and a decrease in sinusoidal
Oatp2 and Ntcp in mutant mice are
observed. Also, a net downregulation of
Mrp2 and Mrp4 is evident in absence of
Foxa2. These defects entrain an accumu-
lation of BA in the hepatocyte and in-
crease the vulnerability of the liver against
toxic stimuli (Figure 1B). In addition, re-
duced gene expression of phase I and II
enzymes such as Cyp3A11 and Slc27a5
in mutant mice is responsible for reduced
BA conjugation and hydroxylation, which
results in impaired ability of the hepato-
cyte to detoxify BA. Combining biochem-
ical and molecular approaches, Kaestner278 Cell Metabolism 8, October 8, 2008 ª20and coworkers (Bochkis et al., 2008)
were able to show that transporters such
as Mrp2 and Oatp2 as well as enzymes
such as Cyp3a11 and Slc27a5 are direct
target of Foxa2.
This elegant piece of work promotes
Foxa2 within the players in the battle
against cholestasis. Indeed, when hepatic
Foxa2-deficient mice are challenged
a diet enriched in cholic acid, the result
is net liver injury. Furthermore, the finding
of reduced Foxa2 expression in human
liver samples from cholestatic patients
leads to the speculation that low hepatic
Foxa2 levels might play a role or exacer-
bate human cholestatic disease. As for
any intriguing discovery, we now look for-
ward to hearing more from this player and
to add mechanistic insights. First, it would
be great to measure the actual bile flow,
biliary BA concentration, and the total
BA pool size to discriminate between he-
patocellular injury and cholestasis. Also,
the amount of biliary and intestinal BA is
probably more important than hepatic
intracellular BA levels per se to reconsti-
tute the negative feed-back that controls
hepatic bile acid synthesis (Inagaki et al.,
2005). Then, given the observed tran-
scriptional changes in biosynthetic en-
zymes (Cyp7a1, Cyp7b1, Cyp8b1, and
Cyp27a1), one would speculate that these
mice might present a basal modification in
the total BA hydrophobicity index, which
is the main determinant of their toxicity.
Finally, apart from being sensitive to
cholic acid feeding, would these mice be
more susceptible than normal mice to08 Elsevier Inc.chemical or surgical models of intra- and
extrahepatic cholestasis? Addressing
these metabolic points is an essential
step to support the intriguing translational
plan of targeting Foxa2 (re)activation in
cholestasis.
REFERENCES
Bochkis, I.M., Rubins, N.E., White, P., Furth, E.E.,
Friedman, J.R., and Kaestner, K.H. (2008). Nat.
Med. 14, 828–836.
Goodwin, B., Jones, S.A., Price, R.R., Watson,
M.A., McKee, D.D., Moore, L.B., Galardi, C.,
Wilson, J.G., Lewis, M.C., Roth, M.E., et al.
(2000). Mol. Cell 6, 517–526.
Hofmann, A.F. (1999). News Physiol. Sci. 14, 24–
29.
Inagaki, T., Choi, M., Moschetta, A., Peng, L.,
Cummins, C.L., McDonald, J.G., Luo, G., Jones,
S.A., Goodwin, B., Richardson, J.A., et al. (2005).
Cell Metab. 2, 217–225.
Lu, T.T., Makishima, M., Repa, J.J., Schoonjans,
K., Kerr, T.A., Auwerx, J., and Mangelsdorf, D.J.
(2000). Mol. Cell 6, 507–515.
Sund, N.J., Ang, S.L., Sackett, S.D., Shen, W.,
Daigle, N., Magnuson, M.A., and Kaestner, K.H.
(2000). Mol. Cell. Biol. 20, 5175–5183.
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx,
J., and Schoonjans, K. (2008). Nat. Rev. Drug
Discov. 7, 678–693.
Trauner, M., Meier, P.J., and Boyer, J.L. (1998). N.
Engl. J. Med. 339, 1217–1227.
Wolfrum, C., Asilmaz, E., Luca, E., Friedman, J.M.,
and Stoffel, M. (2004). Nature 432, 1027–1032.
Zhang, L., Rubins, N.E., Ahima, R.S., Greenbaum,
L.E., and Kaestner, K.H. (2005). Cell Metab. 2,
141–148.
